Dr. Jason M. Fixler
Claim this profileSinai Hospital of Baltimore
Expert in Cancer
Expert in Neuroblastoma
55 reported clinical trials
106 drugs studied
About Jason M. Fixler
Education:
- Obtained MD from the University of Maryland School of Medicine in 2009.
- Completed Residency in Diagnostic Radiology at Johns Hopkins Hospital in 2014.
- Finished Fellowship in Neuroradiology at Johns Hopkins Hospital in 2015.
Experience:
- Assistant Professor of Radiology and Radiological Science at the Johns Hopkins University School of Medicine.
- Specializes in neuroradiology and diagnostic radiology.
- Affiliated with Sinai Hospital of Baltimore.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Neuroblastoma
Global LeaderStage IV
MYC positive
MYC negative
Affiliated Hospitals
Clinical Trials Jason M. Fixler is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Health Study After Leukemia Treatment
for People With Down Syndrome
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.
Recruiting1 award N/A10 criteria
More about Jason M. Fixler
Clinical Trial Related8 years of experience running clinical trials · Led 55 trials as a Principal Investigator · 20 Active Clinical TrialsTreatments Jason M. Fixler has experience with
- Cyclophosphamide
- Etoposide
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
Breakdown of trials Jason M. Fixler has run
Cancer
Neuroblastoma
Brain Tumor
Osteosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jason M. Fixler specialize in?
Jason M. Fixler focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Jason M. Fixler currently recruiting for clinical trials?
Yes, Jason M. Fixler is currently recruiting for 19 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Jason M. Fixler has studied deeply?
Yes, Jason M. Fixler has studied treatments such as Cyclophosphamide, Etoposide, Doxorubicin Hydrochloride.
What is the best way to schedule an appointment with Jason M. Fixler?
Apply for one of the trials that Jason M. Fixler is conducting.
What is the office address of Jason M. Fixler?
The office of Jason M. Fixler is located at: Sinai Hospital of Baltimore, Baltimore, Maryland 21215 United States. This is the address for their practice at the Sinai Hospital of Baltimore.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.